Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice

P Millar, N Pathak, Vadivel Parthsarathy, AJ Bjourson, M O'Kane, V Pathak, Charlotte Moffett, Peter Flatt, Victor A Gault

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)


This study assessed the metabolic and neuroprotective actions of the sodium glucose co-transporter-2 inhibitor dapagliflozin in combination with the GLP-1 agonist liraglutide in dietary-induced diabetic mice. Mice administered low-dose streptozotocin (STZ) on a high fat diet received dapagliflozin, liraglutide, dapagliflozin-plus-liraglutide (DAPA-Lira) or vehicle once-daily over 28 days. Energy intake, body weight, glucose and insulin concentrations were measured at regular intervals. Glucose tolerance, insulin sensitivity, hormone and biochemical analysis, dual-energy x-ray absorptiometry densitometry, novel object recognition, islet and brain histology were examined. Once-daily administration of DAPA-Lira resulted in significant decreases in body weight, fat mass, glucose and insulin concentrations, despite no change in energy intake. Similar beneficial metabolic improvements were observed regarding glucose tolerance, insulin sensitivity, HOMA-IR, HOMA-β, HbA1c, and triglycerides. Plasma glucagon, GLP-1 and IL-6 levels were increased and corticosterone concentrations decreased. DAPA-Lira treatment decreased alpha cell area and increased insulin content compared to dapagliflozin monotherapy. Recognition memory was significantly improved in all treatment groups. Brain histology demonstrated increased staining for doublecortin (number of immature neurons) in dentate gyrus and synaptophysin (synaptic density) in stratum oriens and stratum pyramidale. These data demonstrate that combination therapy of dapagliflozin and liraglutide exerts beneficial metabolic and neuroprotective effects in diet-induced diabetic mice. Our results highlight important personalised approach in utilising liraglutide in combination with dapagliflozin, instead of either agent alone, for further clinical evaluation in treatment of diabetes and associated neurodegenerative disorders.
Original languageEnglish
Pages (from-to)255-267
JournalJournal of Endrocrinology
Issue number3
Publication statusAccepted/In press - 23 Jun 2017


  • dapagliflozin
  • diabetes
  • GLP-1
  • glucagon
  • liraglutide


Dive into the research topics of 'Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice'. Together they form a unique fingerprint.

Cite this